Repositioning metformin and propranolol for colorectal and triple negative breast cancers treatment
Drug repositioning refers to new uses for existing drugs outside the scope of the original medical indications. This approach fastens the process of drug development allowing fnding efective drugs with reduced side efects and lower costs. Colorectal cancer (CRC) is often diagnosed at advanced stages...
Guardado en:
| Autores principales: | Anselmino, L. E., Baglioni, M. V., Malizia, Florencia, Cesatti Laluce, N., Borini Etichetti, Carla María, Martínez Marignac, V. L., Rozados, Viviana, Scharovsky, O. G., Girardini, Javier, Rico, M. J., Menacho Márquez, Mauricio |
|---|---|
| Formato: | article artículo publishedVersion |
| Lenguaje: | Inglés |
| Publicado: |
Nature Research
2022
|
| Materias: | |
| Acceso en línea: | http://hdl.handle.net/2133/23319 http://hdl.handle.net/2133/23319 |
| Aporte de: |
Ejemplares similares
-
Metformin and propranolol combination prevents cancer progression and metastasis in different breast cancer models
por: Rico, María José, et al.
Publicado: (2018) -
A Multilayer Network Approach for Guiding Drug Repositioning in Neglected Diseases
por: Berenstein, A.J., et al. -
A Multilayer Network Approach for Guiding Drug Repositioning in Neglected Diseases
Publicado: (2016) -
Achievements and challenges in the use of metronomics for the treatment of breast cancer
por: Scharovsky, O. Graciela, et al.
Publicado: (2020) -
How Can Network-Pharmacology Contribute to Antiepileptic Drug Development?
por: Di Ianni, Mauricio Emiliano, et al.
Publicado: (2014)